To the full analysis
BioCryst Pharmaceuticals stock: growth
BCRXBioCryst Pharmaceuticals reported $874.84M in revenue for fiscal 2025, up 94.1% on the prior year, up 117.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
29.7%
per year from 2006 to 2025, per share 16.9%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 117.9% | 33.6% | 29.7% |
| Revenue per share | 108.2% | 20.2% | 16.9% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $6.21M | −$43.62M | −$16.75M |
| 2007 | $71.24M | −$29.06M | $3.32B |
| 2008 | $56.56M | −$24.73M | −$22.09M |
| 2009 | $74.59M | −$13.45M | −$16.82M |
| 2010 | $63.5M | −$32.73M | −$28.88M |
| 2011 | $19.64M | −$56.95M | −$32.31M |
| 2012 | $26.29M | −$39.08M | −$37.51M |
| 2013 | $17.33M | −$30.11M | −$26.56M |
| 2014 | $13.61M | −$45.19M | −$38.66M |
| 2015 | $48.26M | −$43.02M | −$18.24M |
| 2016 | $26.35M | −$55.14M | −$58.72M |
| 2017 | $25.19M | −$65.78M | −$41.47M |
| 2018 | $20.65M | −$101.25M | −$92.93M |
| 2019 | $48.84M | −$108.9M | −$89.93M |
| 2020 | $17.81M | −$182.81M | −$137.73M |
| 2021 | $157.17M | −$184.06M | −$144.54M |
| 2022 | $270.83M | −$247.12M | −$163.2M |
| 2023 | $331.41M | −$226.54M | −$97.31M |
| 2024 | $450.71M | −$88.88M | −$53.14M |
| 2025 | $874.84M | $263.86M | $327.41M |
Revenue by segment
How BioCryst Pharmaceuticals, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Product$623.2M71%
- License$244.0M28%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Product | $623.15M | 71.2% |
| License | $243.98M | 27.9% |
| Total revenue | $874.84M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 11 Sep 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.